Clinical Trials Sponsored by Zenith Epigenetics

Total 135 results

Zenith Epigenetics

Completed

A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

United States
Zenith Epigenetics

Completed

A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

United States
Zenith Epigenetics

Enrolling by invitation

Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol

mCRPC

United States
Zenith Epigenetics

Withdrawn

Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML

Acute Myeloid Leukemia | Lymphoproliferative Malignancies

United States
Zenith Epigenetics
Pfizer; Newsoara Biopharma Co., Ltd.

Active, not recruiting

A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer

United States, Belgium, China, Spain
Memorial Sloan Kettering Cancer Center
Zenith Epigenetics

Recruiting

A Study of ZEN003694 in People With Squamous Cell Lung Cancer

Squamous Cell Lung Cancer

United States
Haider Mahdi
GlaxoSmithKline; Zenith Epigenetics

Recruiting

ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors

Ovarian Cancer | Recurrent Solid Tumors

United States
Haider Mahdi
Pfizer; Zenith Epigenetics

Recruiting

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
Zenith Epigenetics
Astellas Pharma Inc; Newsoara Biopharma Co., Ltd.

Recruiting

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

United States, China
Epigenomics, Inc

Completed

PRESEPT Study: Evaluation of SEPT9 Biomarker Performance for Colorectal Cancer Screening (PRESEPT)

Colorectal Cancer

United States, Germany
Epigenomics, Inc

Recruiting

Longitudinal Performance of Epi proColon (PERT)

Colorectal Neoplasms | Colorectal Cancer

United States
Epigenomics, Inc

Active, not recruiting

CRC Detection Reliable Assessment With Blood (CRC-DRAW)

Gastrointestinal Neoplasms | Colonic Diseases, Functional | Intestinal Neoplasms | Rectal Diseases | Colorectal Cancer | Adenoma | Rectal Cancer | Polyps | Colon Cancer | Colon Disease | Colon Polyp | Intestinal Disease | Colon Lesion | Colon Neoplasm | Adenomas Colon | Rectal Polyp

United States
Epigenomics, Inc

Completed

Specimens for Septin 9 Performance (SPR0012)

Colorectal Cancer
Epigenomics, Inc

Completed

Plasma-based Colorectal Cancer Screening Research & Development

Colo-rectal Cancer

United States
Epigenomics, Inc

Completed

Head to Head Study Epi proColon and FIT

Colorectal Cancer

United States, Puerto Rico
Epigenomics, Inc

Completed

Adherence to Minimally Invasive Testing (ADMIT)

Colorectal Cancer

United States
Epigenomics, Inc

Completed

Detection of Colorectal Cancer in Peripheral Blood by Septin 9 DNA Methylation Assay

Colorectal Cancer

Hungary, Germany
Epigenetix, Inc.

Recruiting

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors

Castrate Resistant Prostate Cancer | NUT Carcinoma

United States
Rahul Aggarwal
Merck Sharp & Dohme LLC; U.S. Army Medical Research and Development Command; Zenith...

Recruiting

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma | Metastatic Prostate Small Cell Carcinoma

United States
Suzhou Zenith Vascular Scitech Co., Ltd.

Not yet recruiting

Stent-Retriever for Acute Massive Pulmonary Embolism (SRAME) (SRAME)

PE - Pulmonary Embolism | PE - Pulmonary Thromboembolism

China
Suzhou Zenith Vascular Scitech Co., Ltd.

Completed

A Prospective, Multi-center and Randomized Controlled Trial of Tianyi Revascularization Device in Acute Ischemic Stroke

Acute Ischemic Stroke | Large Vessel Occlusion | AIS | Thrombectomy

China
Veniti

Withdrawn

VERITAS: An Evaluation of the Veniti Vidi Retrievable Inferior Vena Cava Filter System in Patients at Risk for Pulmonary Embolism (VERITAS)

Deep Vein Thrombosis | Pulmonary Embolus

New Zealand, Australia
Epigenomics, Inc
Innovis LLC

Completed

HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma | Cirrhosis, Liver | Liver Cancer | Hepatic Cirrhosis

United States
Athenex, Inc.
PharmaEssentia; Zenith Technology Corporation Limited

Completed

A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients

Solid Tumor

New Zealand, United Kingdom, Taiwan, Australia
Athenex, Inc.
PharmaEssentia; Zenith Technology Corporation Limited

Completed

A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel

Solid Tumor

New Zealand, Taiwan, Australia
University of Pennsylvania
Epigenomics, Inc

Completed

Preliminary Evaluation of Septin9 in Patients With Hereditary Colon Cancer Syndromes (Septin9)

Colorectal Cancer | Lynch Syndrome | Familial Adenomatous Polyposis | Map Syndrome | Hnpcc

United States
University Hospital, Essen
Epigenomics, Inc

Completed

Methylation Level of SHOX2 in Endobronchial Ultrasound With Real-time Guided Transbronchial Needle Aspiration for Lung Cancer Staging

Lung Cancer With Mediastinal Lymph Node Involvement

Germany
Next Science TM
Advancing the Zenith of Healthcare

Terminated

Evaluating Wound Healing With Next Science Gel & Wash.

Chronic Wound

United States
Asofarma S.A.I. y C.
Zenith Technology Corporation Limited

Completed

Bioequivalence Study of a Test Capsule Formulation of Fingolimod With the Reference Capsule Formulation of Fingolimod

Healthy Volunteers

New Zealand
Epigenomics, Inc
Emory University; Kaiser Permanente

Withdrawn

Assessment of Septin9 Biomarker for Detection of Colorectal Cancer in Patients With Positive Fecal Immunochemical Test

Colorectal Cancer

United States
Suzhou Zenith Vascular Scitech Co., Ltd.
Xuanwu Hospital, Beijing

Recruiting

Timing Carotid Stent Clinical Study for the Treatment of Carotid Artery Stenosis（Timing Trial）

Stroke | Ischemic Stroke | Carotid Artery Diseases | Carotid Artery Stenosis

China
Cantonal Hospital Zenica

Completed

Euthyroid Sick Syndrome in Septic Shock

Septic Shock

Bosnia and Herzegovina
Cantonal Hospital Zenica

Completed

Thyroid Hormone Supplementation in Patients With Septic Shock

Septic Shock | Euthyroid Sick Syndromes

Bosnia and Herzegovina
Cantonal Hospital Zenica

Completed

Coagulation Disturbances in COVID-19 Septic Patients

Sepsis | Septic Shock | Coagulation Disorder | COVID 19 Associated Coagulopathy

Bosnia and Herzegovina
Life Length SL

Completed

Telomere Associated Variables (TAVs) in Prostate Cancer

Prostate Cancer

Spain, United States
Cantonal Hospital Zenica

Completed

Early SARS-CoV-2 Tracheostomy

Tracheostomy | Metabolic Disturbance | Characteristics Disease

Bosnia and Herzegovina
Cantonal Hospital Zenica

Completed

Analgosedation for Elective Colonoscopy

Pain | Side Effect

Bosnia and Herzegovina
Fondation Edith Seltzer

Completed

Respiratory Muscle Endurance Training in Obese Patients

Obesity

France
Nermina Rizvanović

Completed

Preoperative Administration of Oral Carbohydrate Drink, Neutrophil/Lymphocyte Ratio and Postoperative Complications

Postoperative Complications | Lymphocyte | Neutrophil

Bosnia and Herzegovina
Spanish Oncology Genito-Urinary Group

Completed

Clinical Trial With Vinflunine as Maintenance Therapy in Metastatic Urothelial Cancer (MAJA)

Carcinoma, Transitional Cell

Spain
Spanish Oncology Genito-Urinary Group

Completed

Validation of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Prognostic Classification for Targeted Therapies (TKI/mTOR Inhibitors) in Second Line After First Line Treatment With Pazopanib (Spazo-2)

Metastatic Renal Cell Carcinoma

Spain
Spanish Oncology Genito-Urinary Group

Completed

Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma

Adrenocortical Carcinoma

Spain
Spanish Oncology Genito-Urinary Group

Completed

Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy (SOGUG/0107)

Carcinoma Renal Cells

Spain
Spanish Oncology Genito-Urinary Group

Completed

Clinical Trial on the Mixture of G, C and S in Treatment of Patients With RCC (SOGUG-02-06)

Carcinoma, Renal Cell

Spain
Spanish Oncology Genito-Urinary Group

Active, not recruiting

Description of the Population With Genitourinary Tumors and COVID-19 (SOGUGCOVID)

Covid19 | Genito Urinary Cancer

Spain
Nermina Rizvanović

Completed

Preoperative Administration of Oral Carbohydrate Drink and Postoperative Insulin Resistance

Insulin Resistance | Inflammatory Response | Length of Stay | Exaggerated Well-Being

Bosnia and Herzegovina
Spanish Oncology Genito-Urinary Group

Completed

Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy (SPAZO)

Metastatic Renal Cell Carcinoma

Spain
Spanish Oncology Genito-Urinary Group

Completed

Study of Weekly Cabazitaxel for Advanced Prostate Cancer

Hormone Refractory Prostate Cancer

Spain
Spanish Oncology Genito-Urinary Group

Completed

Sorafenib and Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent (SOGUG-07-01)

Bladder Cancer

Spain
Spanish Oncology Genito-Urinary Group

Completed

Epidemiological Study to Identify Prognosis and Predictive Biomarkers for Advanced or Metastatic Renal Cell Carcinoma (SOGANG)

Metastatic Renal Cell Carcinoma

Spain

Clinical Trials Sponsored by Zenith Epigenetics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations